Cargando…
Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
PURPOSE OF REVIEW: Adalimumab is one of the top-selling drugs worldwide. Its imminent patent expiration has seen the emergence of numerous biosimilar agents. In this article, we recap the evidence from bio-originator trials in rheumatoid arthritis (RA) to provide context for a critical review of bio...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6097048/ https://www.ncbi.nlm.nih.gov/pubmed/30094742 http://dx.doi.org/10.1007/s11926-018-0769-6 |